| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/01/2011 | US20110212047 Polymer Therapy for the Treatment of Chronic Microvascular Diseases |
| 09/01/2011 | US20110212046 Alternating ring-opening metathesis polymerization |
| 09/01/2011 | US20110212034 Sublingual Buccal Effervescent |
| 09/01/2011 | US20110212031 Novel substituted azabenzoxazoles |
| 09/01/2011 | US20110212026 Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system |
| 09/01/2011 | US20110212023 TADG-15: an extracellular serine protease overexpossed in carcinomas |
| 09/01/2011 | US20110212021 Targeted oligonucleotide compositions for modifying gene expression |
| 09/01/2011 | US20110210460 Process for producing pellets for pharmaceutical compositions |
| 09/01/2011 | US20110209699 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 09/01/2011 | DE102010010666A1 Use of a fatty acid for the diagnostic and/or therapeutic treatment of a cancer e.g. genitourinary cancer, including prostate cancer, colorectal cancer, breast cancer, lung cancer, malignant melanoma, and head and neck carcinoma |
| 09/01/2011 | DE102009034771B4 Hautschutzmittel Skin protection products |
| 09/01/2011 | CA2828114A1 Cephalosporin derivatives useful as .beta.-lactamase inhibitors and compositions and methods of use thereof |
| 09/01/2011 | CA2791331A1 Modulation of angiogenesis |
| 09/01/2011 | CA2791278A1 Sustained delivery of therapeutic agents to an eye compartment |
| 09/01/2011 | CA2791245A1 Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation |
| 09/01/2011 | CA2791190A1 Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof |
| 09/01/2011 | CA2791177A1 Formulations and methods for nutrient delivery |
| 09/01/2011 | CA2791171A1 Apixaban formulations |
| 09/01/2011 | CA2791166A1 Pyrazolopyrimidine compounds and their use as pde10 inhibitors |
| 09/01/2011 | CA2791164A1 Adhesive patch containing bisoprolol |
| 09/01/2011 | CA2791162A1 Oxadiazole compounds, their preparation and use |
| 09/01/2011 | CA2791114A1 Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
| 09/01/2011 | CA2791105A1 Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
| 09/01/2011 | CA2791103A1 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3-d] pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions |
| 09/01/2011 | CA2791100A1 Bisaryl-bonded aryltriazolones and use thereof |
| 09/01/2011 | CA2790993A1 Pyrrolidine substituted flavones for the treatment of inflammatory disorders |
| 09/01/2011 | CA2790959A1 Combination of a centrally-acting analgesic and a selective cyclooxygenase - 2 inhibitor anti-inflammatory agent for the treatment of inflammation and pain in the veterinary field |
| 09/01/2011 | CA2790952A1 Compounds as bradykinin b1 antagonists |
| 09/01/2011 | CA2790946A1 Treatment of dermatological allergic conditions |
| 09/01/2011 | CA2790918A1 Pharmaceutical or neutraceutical formulation |
| 09/01/2011 | CA2790901A1 Amine polymers for use as bile acid sequestrants |
| 09/01/2011 | CA2790899A1 Polyimidazoles for use as bile acid sequestrants |
| 09/01/2011 | CA2790820A1 Methods of using (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid |
| 09/01/2011 | CA2790817A1 Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation |
| 09/01/2011 | CA2790811A1 Formulations for oral delivery of adsorbents in the gut |
| 09/01/2011 | CA2790708A1 Oral b12 therapy |
| 09/01/2011 | CA2790703A1 Estrogen receptor ligands and methods of use thereof |
| 09/01/2011 | CA2790646A1 Silicon-containing biodegradable material for anti-inflammatory therapy |
| 09/01/2011 | CA2790610A1 Biodegradable material containing silicon, for pro-angiogenetic therapy |
| 09/01/2011 | CA2790302A1 Dimeric iap inhibitors |
| 09/01/2011 | CA2790199A1 Trimethoxyphenyl inhibitors of tyrosine kinase |
| 09/01/2011 | CA2789750A1 Ghrelin receptor agonist for treatment of cachexia |
| 09/01/2011 | CA2789696A1 Braf mutations conferring resistance to braf inhibitors |
| 09/01/2011 | CA2789458A1 Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds |
| 09/01/2011 | CA2789457A1 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| 09/01/2011 | CA2789140A1 Synthesis of magnolol and its analogue compounds |
| 09/01/2011 | CA2789064A1 Capsule of compound danshen dripping pills |
| 09/01/2011 | CA2788659A1 Veterinary compositions |
| 09/01/2011 | CA2788600A1 Compositions for targeted delivery of sirna |
| 09/01/2011 | CA2788440A1 Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| 09/01/2011 | CA2788333A1 Method of accelerating corneal wound healing |
| 09/01/2011 | CA2787965A1 Oral care compositions |
| 09/01/2011 | CA2787952A1 Anti-angiogenesis therapy for the treatment of ovarian cancer |
| 09/01/2011 | CA2786314A1 Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| 09/01/2011 | CA2785694A1 Coated solid montelukast preparation |
| 08/31/2011 | EP2362221A1 Antagonists of HMG1 for treating inflamatory conditions |
| 08/31/2011 | EP2362218A2 Methods of monitoring the efficacy of farnesyltransferase inhibitors |
| 08/31/2011 | EP2361981A1 RNA sequence-specific mediators of RNA interference |
| 08/31/2011 | EP2361978A1 Polypeptides capable of eliciting an immune reaction against cancer |
| 08/31/2011 | EP2361928A1 Truncated fragments of alpha-synuclein in Lewy body disease |
| 08/31/2011 | EP2361923A2 Oligoribonucleotides and ribonucleases for cleaving RNA |
| 08/31/2011 | EP2361922A1 Intermediate to HCV-Nucleoside Inhibitors |
| 08/31/2011 | EP2361921A2 Novel bicyclonucleoside and oligonnucleotide analogue |
| 08/31/2011 | EP2361920A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity |
| 08/31/2011 | EP2361918A1 Novel prostaglandin e1 derivative, and nanoparticle having same encapsulated therein |
| 08/31/2011 | EP2361914A1 [(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders. |
| 08/31/2011 | EP2361913A1 Anti-infective agents |
| 08/31/2011 | EP2361912A1 Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| 08/31/2011 | EP2361911A1 Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| 08/31/2011 | EP2361910A1 Compound having tafia inhibitory activity |
| 08/31/2011 | EP2361908A1 Pyrimidine compounds useful for the treatment of CNS diseases |
| 08/31/2011 | EP2361907A1 The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof |
| 08/31/2011 | EP2361905A1 Heterocyclic Inhibitors of MEK and methods of use thereof |
| 08/31/2011 | EP2361904A1 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof |
| 08/31/2011 | EP2361903A1 Benzenoid ansamycin derivative |
| 08/31/2011 | EP2361902A1 4,6-diaminonicotinamide compound |
| 08/31/2011 | EP2361627A2 Composition for prevention or treatment of eye diseases |
| 08/31/2011 | EP2361626A1 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 08/31/2011 | EP2361625A1 Methods and compositions for the treatment of hyperlipidemia |
| 08/31/2011 | EP2361624A1 Oxazole derivatives and their use as tyrosine kinase inhibitors |
| 08/31/2011 | EP2361623A1 Composition comprising a polyphenol salt and corresponding use |
| 08/31/2011 | EP2361622A1 Use of lipoxin analogs to promote cell defense against gram-negative infections |
| 08/31/2011 | EP2361621A1 Human carbamyl phosphate synthetase I polymorphism and diagnostic and therapeutic methods relating thereto |
| 08/31/2011 | EP2361620A1 Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome |
| 08/31/2011 | EP2361619A1 Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer |
| 08/31/2011 | EP2361618A2 Compositions for treating or preventing obesity and insulin resistance disorders |
| 08/31/2011 | EP2361615A1 Dipyridamole prolonged-release tablet |
| 08/31/2011 | EP2361612A2 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 08/31/2011 | EP2361611A2 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 08/31/2011 | EP2361609A1 Sustained release small molecule drug formulation |
| 08/31/2011 | EP2361513A1 DHA- and EPA-rich nutritional ingredient |
| 08/31/2011 | EP2361306A1 Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
| 08/31/2011 | EP2361256A1 Cyclohexenyl nucleic acid analogs |
| 08/31/2011 | EP2361254A1 Raf inhibitors and their uses |
| 08/31/2011 | EP2361253A1 Compounds |
| 08/31/2011 | EP2361251A1 Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| 08/31/2011 | EP2361250A1 Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof |
| 08/31/2011 | EP2361248A1 Heteroaryl compounds and uses thereof |
| 08/31/2011 | EP2361247A2 Flupirtine hydrochloride maleic acid cocrystal |
| 08/31/2011 | EP2361246A1 Oxopiperidinyl and pyranyl sulfonamides as ampa potentiators |